Compliance and enforcement
We monitor and enforce compliance with laws that regulate health products.
How we manage compliance
We take a risk-based, evidence-drive approach that puts public safety first. Under the Therapeutic Goods Act 1989, we work to protect Australians by educating industry, assessing risks and taking action when needed.
Watch our video to learn more or explore our regulatory compliance framework.
Report a breach
We want to hear about:
- breaches of the Therapeutic Goods Act
- counterfeit products
- questionable practices
- non-compliant advertising related to therapeutic goods.
Know our compliance principles
We have re-aligned our approach to determining compliance priorities for 2026 and 2027. The new approach sees our priorities structured around five compliance principles, each supported by routinely reviewed priority focus areas. These principles guide how we address illegal import, export, manufacture, supply and advertising of therapeutic goods.
The five principles are:
- Safeguarding therapeutic goods
- Educate to empower
- Protect those most at risk
- Leverage digital capability
- Strengthen enforcement.
Learn more about our compliance principles
Find a compliance outcome
When we receive a report of a breach, we investigate and take action based on the level of risk to public health and safety. Our actions range from education and warnings to fines and legal action.
Understand the ways we respond to breaches of therapeutic good regulations and find the latest outcomes.
Page history
'Know our compliance principles' section updated.
Original publication.
'Know our compliance principles' section updated.
Original publication.
Latest alerts
-
The Therapeutic Goods Administration (TGA) is advising consumers that several sexual enhancement products have been found to contain undeclared ingredients and may pose a serious risk to your health.
-
We are advising consumers that ‘Pharmatech’ branded MK-677 capsules (containing ibutamoren) may pose a serious risk to your health and should not be taken.
-
We are advising consumers that Artri Ajo King tablets may pose a serious risk to your health and should not be taken.
Latest articles
-
Company, pharmacists issued $71k of infringement notices for alleged unlawful melatonin imports
TGA has issued 10 infringement notices totalling $71,280 to Gezond Pty Ltd and 3 registered pharmacists. -
Enforcement action disrupts illicit vape distribution network in Sydney
The TGA, working with the NSW Police Force and other state and Commonwealth enforcement agencies, supported coordinated enforcement operations targeting a company allegedly involved in the importation, storage and distribution of vaping goods, nicotine pouches, illicit tobacco and other unlawful products. -
TGA flexes its muscle against illegal peptides and steroids
TGA with the assistance of the NSW Police has seized more than $120,000 of illicit peptide and anabolic steroid products from 2 residential premises in New South Wales allegedly linked to a social media influencer.
Latest publications
-
This report summarises the outcomes of the Pharmacovigilance Inspection Program in the 2-year period. The deficiencies identified are presented along with case studies of critical deficiencies from this reporting period, to support medicine sponsors in the continual improvement of their pharmacovigilance systems.
-
The report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
Open consultations
-
Consultation: Proposed changes to support automated decision making (ADM) for applications to change listed medicines
We are seeking feedback on proposed changes to support automated decision making (ADM) for applications to change listed medicines.